SIgA in various pulmonary diseases

Wang, Xintian; Zhang, Jun; Wu, Yan; Xu, Yuncong; Zheng, Jinxu

doi:10.1186/s40001-023-01282-5

Cited by 6 publications

(3 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also aligns with responses elicited by other COVID-19 vaccines used in this demographic, such as Sinovac Biotech's CoronaVac COVID-19 vaccine [26] and the Oxford/AstraZeneca ChadOx1-S COVID-19 vaccine [27], collectively supporting the vaccine's effectiveness in this landscape. These finding align with literature that shows the importance of mucosal immunity in respiratory infections [28][29][30] and could have implications for future vaccine designs and public health strategies [28][29][30].…”

Section: Discussionsupporting

confidence: 89%

The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in A 12-Month Ugandan Cohort

Serwanga,

Kato,

Ankunda

et al. 2024

Preprint

View full text Add to dashboard Cite

The study evaluated the immune response to the Janssen Ad26.COV2.S COVID-19 vaccine in a Ugandan cohort, focusing on spike (S) and nucleocapsid (N) protein-directed antibodies. The aim was to assess the longevity and robustness of the elicited antibodies, aligning with breakthrough infections and prior exposure to SARS-CoV-2. The study involved 319 specimens collected over 12 months from 60 vaccinees aged 18 to 64. Binding antibodies were quantified using a validated ELISA method to measure SARS-CoV-2-specific IgG, IgM, and IgA levels against the S and N proteins. The results showed that baseline seropositivity for S-IgG was high at 67%, increasing to 98% by day 14 and consistently stayed above 95% for up to 12 months. However, S-IgM responses remained suboptimal. An increased S-IgA serpositivity rate doubled from 40% at baseline to 86% just two weeks following the initial vaccine dose, indicating sustained and robust mucosal immunity. An increase in N-IgG levels at nine months post-vaccination suggested breakthrough infections in eight cases. Baseline cross-reactivity influenced spike-directed antibody responses, with those with pre-existing S-IgG antibodies showing higher responses. The vaccine demonstrated robust and long-lasting immune responses, with significant implications for regions where administering follow-up doses is challenging.

show abstract

Section: Discussionsupporting

confidence: 89%

The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in A 12-Month Ugandan Cohort

Serwanga,

Kato,

Ankunda

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, breakthrough infections were more frequent among the participants who were S-IgG seronegative at baseline, thus suggesting an advantage of multiple antigenic exposure in eliciting protective vaccine-induced antibodies. Our findings also align with responses elicited by other COVID-19 vaccines used in this demographic, such as Sinovac Biotech's CoronaVac COVID-19 vaccine (30), the Oxford/AstraZeneca ChadOx1-S COVID-19 vaccine (31), the Pfizer-BioNTech BNT162b2 Vaccine (24), and Moderna's mRNA 1273 (25) collectively supporting the vaccine's effectiveness in this landscape and could have implications for future vaccination and public health strategies (32)(33)(34).…”

Section: Discussionsupporting

confidence: 79%

The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort

Serwanga,

Kato,

Oluka

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThe study investigation examined the immune response to the Janssen Ad26.COV2.S COVID-19 vaccine within a Ugandan cohort, specifically targeting antibodies directed against spike (S) and nucleocapsid (N) proteins. We aimed to examine the durability and robustness of the induced antibody response while also assessing occurrences of breakthrough infections and previous anti-Spike seropositivity to SARS-CoV-2.MethodsThe study included 319 specimens collected over 12 months from 60 vaccinees aged 18 to 64. Binding antibodies were quantified using a validated ELISA method to measure SARS-CoV-2-specific IgG, IgM, and IgA levels against the S and N proteins.ResultsThe results showed that baseline seropositivity for S-IgG was high at 67%, increasing to 98% by day 14 and consistently stayed above 95% for up to 12 months. However, S-IgM responses remained suboptimal. A raised S-IgA seropositivity rate was seen that doubled from 40% at baseline to 86% just two weeks following the initial vaccine dose, indicating sustained and robust peripheral immunity. An increase in N-IgG levels at nine months post-vaccination suggested breakthrough infections in eight cases. Baseline cross-reactivity influenced spike-directed antibody responses, with individuals harbouring S-IgG antibodies showing notably higher responses.DiscussionRobust and long lasting vaccine and infection-induced immune responses were observed, with significant implications for regions where administering subsequent doses poses logistical challenges.

show abstract

“…The transient, subdued S-IgM response observed aligns with its typical early appearance and subsequent decline in favor of memory responses, as evidenced in natural infections within this population ( 20 ) and others ( 31 , 32 ). S-IgA, essential in mucosal defence against SARS-CoV-2 ( 33 ), initially rose but declined by six months post-prime, providing insights into the temporal dynamics of mucosal immunity ( 23 , 34 ), which is a crucial role against SARS-CoV-2 ( 35 , 36 ). Breakthrough infections, uniformly distributed across groups irrespective of initial S-IgG levels, were asymptomatic, suggesting the effectiveness of the elicited immunity.…”

Section: Discussionmentioning

confidence: 99%

The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies

Ankunda,

Katende,

Oluka

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThis study aimed to delineate longitudinal antibody responses to the Pfizer-BioNTech BNT162b2 COVID-19 vaccine within the Ugandan subset of the Sub-Saharan African (SSA) demographic, filling a significant gap in global datasets.MethodsWe enrolled 48 participants and collected 320 specimens over 12 months after the primary vaccination dose. A validated enzyme-linked immunosorbent assay (ELISA) was used to quantify SARS-CoV-2-specific IgG, IgM, and IgA antibody concentrations (ng/ml) and optical densities (ODs). Statistical analyses included box plots, diverging bar graphs, and the Wilcoxon test with Bonferroni correction.ResultsWe noted a robust S-IgG response within 14 days of the primary vaccine dose, which was consistent with global data. There was no significant surge in S-IgG levels after the booster dose, contrasting trends in other global populations. The S-IgM response was transient and predominantly below established thresholds for this population, which reflects its typical early emergence and rapid decline. S-IgA levels rose after the initial dose then decreased after six months, aligning with the temporal patterns of mucosal immunity. Eleven breakthrough infections were noted, and all were asymptomatic, regardless of the participants’ initial S-IgG serostatus, which suggests a protective effect from vaccination.DiscussionThe Pfizer-BioNTech BNT162b2 COVID-19 vaccine elicited strong S-IgG responses in the SSA demographic. The antibody dynamics distinctly differed from global data highlighting the significance of region-specific research and the necessity for customised vaccination strategies.

show abstract

SIgA in various pulmonary diseases

Cited by 6 publications

References 129 publications

The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in A 12-Month Ugandan Cohort

The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in A 12-Month Ugandan Cohort

The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort

The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies

Contact Info

Product

Resources

About